Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.

Hoeldtke RD, Bryner KD, Hoeldtke ME, Hobbs G

Clinical autonomic research : official journal of the Clinical Autonomic Research Society11 Oct 2006Cited by 44 (Europe PMC)

PMID17036177DOI10.1007/s10286-006-0373-0PepBankPUB-17036177

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In POTS, octreotide did not improve standing time from 41.2+/-8.4 minutes.
In plain wordsIn POTS, octreotide did not improve standing time compared with the untreated test.
Peptide
Octreotide
Outcome
No significant changeStanding time in POTS
Study
n = 9
Comparator
Untreated standing test
Outcome group
Heart function · Cardiovascular
Studied dose
0.9 micro g/kgAs given in this study (human).
Measurements
Baseline standing time
41.2 minutes
POTS, untreated standing test, +/- 8.4; no octreotide value reported
Source sentences
Summary
Standing time in the patients with POTS was 41.2 +/- 8.4 minutes and not improved by midodrine or octreotide, but increased to 56.3 +/- 2.7 (P < 0.01) minutes following combination therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored.
Summary · context
Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 micro g/kg 8 minutes before testing or combination therapy.
Report a problemFND-1703617701
02HumanNon-randomized trialEfficacy outcome
In POTS, octreotide reduced standing heart rate from 114+/-0.7 to 90.6+/-0.78 bpm (P<0.001).
In plain wordsIn POTS, octreotide lowered standing heart rate compared with the untreated test.
Peptide
Octreotide
Outcome
DecreaseStanding heart rate in POTS
Study
n = 9
Comparator
Untreated standing test
Outcome group
Heart function · Cardiovascular
Studied dose
0.9 micro g/kgAs given in this study (human).
Measurements
Standing heart rate, baseline
114 bpm
POTS, untreated standing test, +/- 0.7
Standing heart rate after octreotide
90.6 bpm
POTS, +/- 0.78
P value vs baseline
< 0.001 P
POTS, octreotide
Source sentences
Summary
The standing heart rate in POTS, 114 +/- 0.7 bpm, was suppressed by midodrine 92.8 +/- 0.7 (P < 0.001), octreotide 90.6 +/- 0.78 (P < 0.001), and combination therapy 84.7 +/- 0.7 (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored.
Summary · context
Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 micro g/kg 8 minutes before testing or combination therapy.
Report a problemFND-1703617702
03HumanNon-randomized trialEfficacy outcome
In orthostatic intolerance, octreotide increased standing time from 36.3+/-3.5 to 56.5+/-3.5 minutes (P<0.05).
In plain wordsIn orthostatic intolerance, octreotide increased standing time compared with the untreated test.
Peptide
Octreotide
Outcome
IncreaseStanding time in orthostatic intolerance
Study
n = 6
Comparator
Untreated standing test
Outcome group
Heart function · Cardiovascular
Studied dose
0.9 micro g/kgAs given in this study (human).
Measurements
Standing time, baseline
36.3 minutes
orthostatic intolerance, untreated standing test, +/- 3.5
Standing time after octreotide
56.5 minutes
orthostatic intolerance, +/- 3.5
P value vs baseline
< 0.05 P
orthostatic intolerance, octreotide
Source sentences
Summary
Standing time of 36.3 +/- 3.5 minutes in the patients with OI improved with midodrine, octreotide and combination therapy (55.5 +/- 3.1, 56.5 +/- 3.5, and 56.6 +/- 3.3, respectively, P < 0.05 for each).
2 context sentences(design, population, supporting numbers)
Summary · context
Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored.
Summary · context
Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 micro g/kg 8 minutes before testing or combination therapy.
Report a problemFND-1703617703
04HumanNon-randomized trialEfficacy outcome
In orthostatic intolerance, standing heart rate was 100+/-.76 bpm before treatment and 84.8+/-.86 following octreotide.
In plain wordsIn orthostatic intolerance, standing heart rate was numerically lower after octreotide than in the untreated test.
Peptide
Octreotide
Outcome
DecreaseStanding heart rate in orthostatic intolerance
Study
n = 6
Comparator
Untreated standing test
Outcome group
Heart function · Cardiovascular
Studied dose
0.9 micro g/kgAs given in this study (human).
Measurements
Standing heart rate, baseline
100 bpm
orthostatic intolerance, untreated standing test, +/- .76
Standing heart rate after octreotide
84.8 bpm
orthostatic intolerance, +/- .86; no P value reported
Source sentences
Summary
Standing heart rate in OI was 100 +/- .76 bpm; following midodrine it was 80.3 +/- .69 (P < 0.05), following octreotide it was 84.8 +/- .86, and following combination therapy it was 71.2 +/- .9 (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored.
Summary · context
Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 micro g/kg 8 minutes before testing or combination therapy.
Report a problemFND-1703617704
05HumanNon-randomized trialEfficacy outcome
In orthostatic intolerance, octreotide increased the Orthostatic Index from 21.1+/-4 to 40.3+/-3.8 (P<0.01).
In plain wordsIn orthostatic intolerance, octreotide increased the Orthostatic Index compared with the untreated test.
Peptide
Octreotide
Outcome
IncreaseOrthostatic Index
Study
n = 6
Comparator
Untreated standing test
Outcome group
Heart function · Cardiovascular
Studied dose
0.9 micro g/kgAs given in this study (human).
Measurements
Orthostatic Index, baseline
21.1 Orthostatic Index
orthostatic intolerance, RR interval versus time AUC, +/- 4
Orthostatic Index after octreotide
40.3 Orthostatic Index
orthostatic intolerance, +/- 3.8
P value vs baseline
< 0.01 P
orthostatic intolerance, octreotide
Source sentences
Summary
After midodrine it was 41.4 +/- 3.5 (P < 0.01), after octreotide 40.3 +/- 3.8 (P < 0.01) and after the combination it was 47.3 +/- 4.6 (P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
The RR interval versus time area under the curve (The Orthostatic Index) was 21.1 +/- 4 in patients with OI.
Summary · context
Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored.
Summary · context
Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 micro g/kg 8 minutes before testing or combination therapy.
Report a problemFND-1703617705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.